Corp., Flemington, New Jersey, and Prestige State Bank, Flemington, New Jersey.

C. Federal Reserve Bank of Richmond (A. Linwood Gill III, Assistant Vice President) 701 East Byrd Street, Richmond, Virginia 23261-4528:

1. First Union Corporation, Charlotte, North Carolina; to acquire additional nonvoting common stock of United Bancshares, Inc., Philadelphia, Pennsylvania, and thereby increase its investment in United Bank of Philadelphia.

D. Federal Reserve Bank of Chicago (Philip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

1. Peotone Bancorp, Inc., Peotone, Illinois, and its subsidiary, Southwest Bancorp, Inc., Worth, Illinois; to retain direct and indirect ownership of 7.98 percent of the voting shares of Bank of the San Juans, Durango, Colorado.

Board of Governors of the Federal Reserve System, November 12, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–30776 Filed 11–17–98; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 2, 1998.

A. Federal Reserve Bank of Boston (Richard Walker, Community Affairs Officer) 600 Atlantic Avenue, Boston, Massachusetts 02106-2204:

1. Fleet Financial Group, Inc., Boston, Massachusetts; to acquire Merrill Lynch Specialists, Inc., New York, New York, and thereby engage in dealing to a limited extent in all types of ineligible securities; and in providing securities brokerage services, pursuant to § 225.28(b)(7)(i) of Regulation Y, and incidental activities (including related securities credit activities and custodial services as well as acting as a ''conduit'' or ''intermediary'' in securities borrowing and lending) *See Fleet Financial Group, Inc.*, 84 Fed. Res. Bull. 227 (1998).

Board of Governors of the Federal Reserve System, November 12, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–30775 Filed 11–17–98; 8:45 am]

BILLING CODE 6210–01–F

GENERAL ACCOUNTING OFFICE

Federal Accounting Standards Advisory Board

AGENCY: General Accounting Office.

ACTION: Notice of Meeting on December 3 and 4.

SUMMARY: Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), as amended, notice is hereby given that the Federal Accounting Standards Advisory Board will hold a two-day meeting on Thursday, December 3 and Friday, December 4, 1998 in room 7C13, the Comptroller General's Briefing Room, of the General Accounting Office building, 441 G St., NW., Washington, DC.

The purposes of the meeting are to: (A) discuss the following issues: (1) Direct Loans and Loan Guarantees, (2) Social Insurance, and (3) Grant Accounting; and (B) hold a roundtable discussion on Accounting for National Property, Plant, and Equipment.

Any interested person may attend the meeting as an observer. Board discussions and reviews are open to the public.

FOR FURTHER INFORMATION, CONTACT: Wendy Comes, Executive Director, 441 G St., NW., Room 3B18, Washington, DC 20548, or call (202) 512–7350.

Authority: Federal Advisory Committee Act. Pub. L. 92–463, sec. 10(a)(2), 86 Stat. 770, 774 (1972) (current version at 5 U.S.C. app. section 10(a)(2) (1988); 41 CFR 101–6.1015 (1990).

Dated: November 13, 1998.

Wendy M. Comes,

Executive Director.

[FR Doc. 98–30869 Filed 11–17–98; 8:45 am]

BILLING CODE 1610–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Financial Institution Data Match.

OMB No.: New.

Description: Section 372 of Pub. L. 104–193, requires State to establish procedures under which the State child support enforcement (IV–D) agency shall enter into agreements with financial institutions doing business in the State for the purpose of securing information leading to the enforcement of child support orders. States will develop and operate, a data match system in which each financial institution will provide quarterly the name, record address, social security number or taxpayer identification number, and other identifying information for each noncustodial parent who maintains an account at such institution and who owes past-due support. H.R. 3130, the ''Child Support Performance and Incentive Act of 1998'', section 506 amends section 452 and 466(a)(17)(A)(i) of the PRWORA of 1996 to permit the Secretary of Health and Human Services, through the Federal Parent Locator Service (FPLS), to aid State CSE agencies in coordinating data matches with multi-state financial institutions.

Respondents: State, Local or Tribal Government.

ANNUAL BURDEN ESTIMATES

Title	Number of respondents	Number of responses per respondent	Average burden per response	Burden
Financial on Data Match Tape	1,886	4	.5	3,772

Estimated Total Annual Burden Hours: 3,772.

Additional Information

Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer.

OMB Comment

OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, NW., Washington, DC 20503, Attn: Ms. Wendy Taylor.

Dated: November 12, 1998.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 98–30843 Filed 11–17–98; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0308]

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).

DATES: Submit written comments on the collection of information by December 18, 1998.

ADDRESSES: Submit written comments on the collection of information to Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attn: Desk Officer for FDA.

FOR FURTHER INFORMATION CONTACT: Denver Presley, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B–26, Rockville, MD 20857, 301–827–1472.

SUPPLEMENTARY INFORMATION: In compliance with section 3507 of the PRA (44 U.S.C. 3507), FDA has submitted the following proposed collection of information to OMB for review and clearance.

Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report—21 CFR Part 510—(OMB Control Number 0910–0012)

Section 512(l) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(l)), 21 CFR 510.300, 510.301, and 510.302 require that applicants of approved new animal drug applications (NADA's), submit within 15-working days of receipt, complete records of reports of certain adverse drug reactions and unusual failure of new animal drugs. Other reporting requirements of adverse reactions to these drugs must be reported annually or semiannually in a specific format.

This continuous monitoring of approved new animal drugs, affords the primary means by which FDA obtains information regarding potential problems in safety and effectiveness of marketed animal drugs and potential manufacturing problems. Data already on file with FDA is not adequate because animal drug effects can change over time and less apparent effects may take years to manifest themselves. Reports are reviewed along with those previously submitted for a particular drug to determine if any change is needed in the product or labeling, such as package insert changes, dosage changes, additional warnings or contraindications, or product reformulation.

Adverse reaction reports are required to be submitted by the drug manufacturer on FDA Forms 1932 or 1932a (voluntary reporting form), following complaints from animal owners or veterinarians. Product defects and lack of effectiveness complaints are submitted to FDA by the drug manufacturer following their own detection of a problem or complaints from product users or their veterinarians also using FDA Forms 1932 and 1932a. Form FDA 2301 is used for the required transmittal of periodic reports and promotional material for new animal drugs. Respondents to this collection of information are applicants of approved NADA's.

In the **Federal Register** of June 10, 1998 (63 FR 31788), the agency requested comments on the proposed collection of information using the reporting forms cited previously. In response, FDA received one comment to the docket. The comment expressed favor in submitting adverse drug reactions, lack of effectiveness and product defect reports (data), electronically and suggested that Form FDA 1932 be formatted in industry standard format (Microsoft Word or Word Perfect), so that these data can be submitted electronically. The Center for Veterinary Medicine (CVM), is developing procedures for electronic submission of adverse drug reactions, lack of effectiveness and product defects. Currently, CVM is not able to accept electronic submission of this specific data until the electronic submission data standards are in place and the hardware/software technology is set up. In the meantime, the current regulations do allow for acceptance of computerized reports under 21 CFR 510.302(c)(1), in lieu of Form FDA 1932. The information contained in a computerized report and the sequence in which it is presented must be equivalent to that required in the hard copy of Form FDA 1932 and should include the valid OMB control number identified with Form FDA 1932, i.e., 0910–0012. The computerized report must be submitted in duplicate to CVM for approval prior to initial use. Further, once the forms are approved and disseminated for use, CVM will post electronic copies via the Worldwide